GlassScriptPhysician profile
Jacob Michael Feagans
NPI 1932389681
$10,571.40
in general payments reported to CMS, 2019-2025
34 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $545 · 2021: $1,265 · 2022: $1,934 · 2023: $1,488 · 2024: $1,759 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,579 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,578.91 |
| Education | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,476.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,375.15 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $992.13 | 2019-2025 | Relistor, Trulance, Xifaxan |
| Pfizer INC. | $551.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $417.14 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $396.48 | 2019-2024 | Sucraid, Sucraid |
| Boston Scientific Corporation | $329.62 | 2025 | Apollo Revise Nxt System, Axonics, General - Therapies |
| Nestle Healthcare Nutrition INC. | $307.34 | 2021-2023 | |
| Gilead Sciences, INC. | $300.10 | 2019-2025 | |
| Celgene Corporation | $264.09 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $229.53 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $214.20 | 2023-2025 | Voquezna |
| Amgen INC. | $192.27 | 2020-2025 | Amjevita, Uplizna, Avsola |
| Madrigal Pharmaceuticals | $187.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Axonics, INC. | $177.35 | 2021-2024 | Axonics |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $173.51 | 2019-2024 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $137.11 | 2024-2025 | Vowst |
| Endogastric Solutions, INC | $121.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $108.01 | 2024 | Dupixent |
| Lilly USA, LLC | $107.31 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $104.35 | 2025 | Tremfya |
| Ardelyx, INC. | $77.04 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $55.40 | 2021-2022 | |
| Fujifilm Healthcare Americas Corporation | $53.81 | 2025 | |
| Redhill Biopharma INC. | $40.50 | 2020-2022 | |
| Shire North American Group INC | $39.75 | 2019 | |
| Genzyme Corporation | $28.94 | 2025 | |
| Ironwood Pharmaceuticals, INC | $27.80 | 2021 | |
| Medtronic, INC. | $21.56 | 2022 | |
| Merck Sharp & Dohme LLC | $19.04 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.28 | 2025 | Rebyota |
| Allergan, INC. | $11.28 | 2020 | |
| Echosens North America, INC. | $11.13 | 2019 | |
| Dynavax Technologies Corporation | $8.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Feagans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.